DermTech presents translational medicine to revolutionize skin care at the American Congress on Biomarkers and Precision Medicine

LA JOLLA, Calif., October 10, 2022–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a noninvasive skin genomics platform, today announced presented today at the Biomarkers & Precision Medicine USA Congress, held October 3-4 in San Diego. 6e The annual event brought together leading speakers from the pharmaceutical, biotechnology and academic sectors, sharing new case studies, innovative data and industry insights.

Erica Montano, Ph.D., DermTech Stratum™ Research Scientist, presented DermTech Stratum’s translational medicine services and its precision-based approach to dermatology. The presentation, titled “Translational Research to Revolutionize Dermatology Care,” focused on the company’s proprietary Smart Sticker™ technology and platform, highlighting its capabilities, specializations and advantages.

By noninvasively capturing genomic and proteomic material in the epidermis, DermTech’s Smart Sticker technology and platform leverages skin gene and protein expression profiles in a clinical research setting to provide precise, objective and useful information; identify biomarkers that may be useful in stratifying a disease of interest or a subgroup of diseases; and determining the patient’s response to a selected therapeutic target. In addition, the integration and implementation of the smart sticker in clinical trials improves patient recruitment in research studies and therefore data collection, as it is generally observed that less than 20% of eligible subjects volunteer for surgical skin biopsy collection due to its invasive nature.

Dr. Montano’s presentation demonstrated the smart sticker’s ability to identify potential subgroups of atopic dermatitis (AD) and psoriasis, which optimizes clinical trial enrollment and diagnostic accuracy, and improves outcomes for patients. She concluded by emphasizing how this technology is poised to potentially revolutionize dermatology research. A recording of his full presentation is available here.

“I am delighted to have the opportunity to present on behalf of DermTech Stratum at the 6e Annual Biomarkers & Precision Medicine USA Congress, sharing our translational medicine services that could revolutionize dermatology care and research and development through precision and personalization,” said Dr. Montano. “By leveraging genomic markers for precision medicine and clinical research, we can better aid in accurate diagnoses and predict and track responses to therapeutic intervention, thereby improving patient care.”

Dr. Montano is a highly experienced researcher specializing in biomarker discovery. She holds a PhD in Biomedical Sciences and Translational Medicine from Cedars Sinai Medical Center. While there, his research focused on understanding the immune defects underlying lupus pathology and identified novel metabolic differences in the immune cells of lupus patients that contributed to genetic reprogramming and increased inflammation.

For more information about DermTech Stratum, visit

About Derma Tech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, made possible by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions of people by providing non-invasive, precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and develops products that assess inflammatory diseases and personalize drug treatments. For more information, please visit DermTech.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. DermTech’s expectations, estimates and projections may differ from its actual results and, accordingly, you should do not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “plan”, “outlook”, “anticipate”, “intend”, “plan”, “may”, “will”, “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, but are not limited to, expectations and assessments regarding: performance, patient benefits, profitability, commercialization and adoption of DermTech’s products and market opportunities for such products, DermTech’s positioning and potential revenue growth, financial outlook and future financial performance, the ability to maintain or improve operating efficiency, implications and interpretations of any study results, expectations regarding reimbursement models or Medicare’s fundraising from commercial payers and related billing practices or number of lives covered; and DermTech’s ability to expand its product offerings and develop ongoing products. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are beyond DermTech’s control and are difficult to predict. Factors that could cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be brought against DermTech; (2) DermTech’s ability to obtain additional financing to develop and commercialize its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) reimbursement for DermTech’s tests by Medicare and commercial payers; (5) the ability of patients or healthcare providers to obtain sufficient coverage or reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain key employees; (7) changes in applicable laws or regulations; (8) market adoption and demand for DermTech’s products and services as well as the possibility that DermTech may be adversely affected by other economic, business and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of DermTech’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including any subsequent filings. DermTech cautions that the above list of factors is not exclusive. You should not place undue reliance on forward-looking statements, which speak only as of the date made. DermTech neither undertakes nor accepts any obligation or undertaking to publicly release updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions or circumstances about which any such statement is made. based.

See the source version on


Steve Kunszabo
(858) 291-1647
[email protected]

About Hector Hedgepeth

Check Also

Folbigg’s life and advances in genetic research

New South Wales will conduct a second inquiry into Kathleen Folbigg’s convictions. At the center …